W
Wanda Michej
Researcher at McGill University
Publications - 25
Citations - 1312
Wanda Michej is an academic researcher from McGill University. The author has contributed to research in topics: GiST & Imatinib mesylate. The author has an hindex of 15, co-authored 25 publications receiving 1220 citations.
Papers
More filters
Journal ArticleDOI
Risk Criteria and Prognostic Factors for Predicting Recurrences After Resection of Primary Gastrointestinal Stromal Tumor
Piotr Rutkowski,Zbigniew Nowecki,Wanda Michej,Maria Debiec-Rychter,Agnieszka Woźniak,Janusz Limon,Janusz A. Siedlecki,Urszula Grzesiakowska,Michał Kąkol,Czesław Osuch,Marcin Polkowski,Stanisław Głuszek,Zbigniew Żurawski,Wlodzimierz Ruka +13 more
TL;DR: The risk criteria for assessing the natural course of primary GISTs were validated, but additional independent prognostic factors—primary tumor location and sex—were also identified.
Journal ArticleDOI
Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes.
Alexander C.J. van Akkooi,Zbigniew Nowecki,Christiane Voit,Gregor Schäfer-Hesterberg,Wanda Michej,Johannes H. W. de Wilt,Piotr Rutkowski,Cornelis Verhoef,Alexander M.M. Eggermont +8 more
TL;DR: This large multicenter dataset establishes that patients with SUB-micrometastases <0.1 mm have the same prognosis as SN negative patients and can be spared a CLND.
Journal ArticleDOI
Prognosis in Patients With Sentinel Node–Positive Melanoma Is Accurately Defined by the Combined Rotterdam Tumor Load and Dewar Topography Criteria
Augustinus P. T. van der Ploeg,Alexander C.J. van Akkooi,Piotr Rutkowski,Zbigniew I. Nowecki,Wanda Michej,Angana Mitra,Julia Newton-Bishop,Martin G. Cook,Iris M.C. van der Ploeg,Omgo E. Nieweg,Mari F.C.M. van den Hout,Paul A. M. van Leeuwen,Christiane Voit,Francesco Cataldo,Alessandro Testori,Caroline Robert,Harald J. Hoekstra,Cornelis Verhoef,Alain Spatz,Alexander M.M. Eggermont +19 more
TL;DR: Patients with metastases < 0.1 mm, especially when present in the subcapsular area only, may be overtreated by a routine CLND and have an MSS that is indistinguishable from that of SN-negative patients, thus the RDC criteria provide a rational basis for decision making in the absence of conclusions provided by randomized controlled trials.
Journal ArticleDOI
Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour – The impact of tumour rupture on patient outcomes
Piotr Rutkowski,Elżbieta Bylina,Agnieszka Wozniak,Zbigniew Nowecki,Czesław Osuch,Maciej Matłok,Tomasz Switaj,Wanda Michej,M Wronski,Stanisław Głuszek,J. Kroc,Anna Nasierowska-Guttmejer,Heikki Joensuu +12 more
TL;DR: The Joensuu criteria, which include 4 prognostic factors (tumour size, site, mitotic count and rupture) and 3 categories for the mitoticcount, were found to be a reliable tool for assessing prognosis of operable GIST.
Journal ArticleDOI
Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors
Jerzy Lasota,Anna Jerzak vel Dobosz,Bartosz Wasag,Agnieszka Wozniak,Ewa Kraszewska,Wanda Michej,Konrad Ptaszyński,Piotr Rutkowski,Maarit Sarlomo-Rikala,Sonja E. Steigen,Regine Schneider-Stock,Jerzy Stachura,Maria Chosia,Gabriel O. Ogun,Wlodzimierz Ruka,Janusz A. Siedlecki,Markku Miettinen +16 more
TL;DR: It is concluded that presence of homozygous KIT exon 11 mutations is associated with malignant course of disease and should be considered an adverse prognostic marker in GISTs.